Ole Weis Bjerrum

Medicine & Life Sciences

1. Primary Myelofibrosis 100%
2. Polycythemia Vera 91%
3. Essential Thrombocythemia 64%
4. Interferons 50%
5. Eosinophilia 34%
6. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 31%
7. Neoplasms 30%
8. Genes 21%
9. Primary Health Care 20%
10. Eosinophils 19%
11. Mutation 19%
12. Leukemia, Myeloid, Chronic Phase 18%
13. Hematology 15%
14. Interferon-alpha 15%
15. Imatinib Mesylate 14%
16. Therapeutics 14%
17. INCB018424 14%
18. Systemic Mastocytosis 13%
19. Gene Expression Profiling 13%
20. Hematologic Neoplasms 13%
21. Vorinostat 13%
22. Dasatinib 13%
23. Methylation 12%
24. Spinal Puncture 11%
25. Databases 10%
26. Safety 10%
27. HLA Antigens 9%
28. Blood Donors 9%
29. Janus Kinase 2 9%
30. Neutropenia 9%
31. Philadelphia Chromosome 8%
32. Epigenomics 8%
33. Blood Cell Count 8%
34. Hydroxyurea 8%
35. Denmark 8%
36. Down-Regulation 8%
37. Mastocytosis 7%
38. Alleles 7%
39. MHC Class I Genes 7%
40. Mast Cells 7%
41. Tissue Donors 7%
42. Hemoglobins 7%
43. MHC Class II Genes 7%
44. Factor VII Deficiency 7%
45. Bone Marrow 7%
46. Systematic Reviews 6%
47. Granulocytes 6%
48. 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide 6%
49. Hypereosinophilic Syndrome 6%
50. Leukocyte Count 6%